Czech National Bank Acquires 1,820 Shares of Solventum Co. (NYSE:SOLV)

Czech National Bank raised its holdings in shares of Solventum Co. (NYSE:SOLV) by 6.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 29,966 shares of the company’s stock after purchasing an additional 1,820 shares during the quarter. Czech National Bank’s holdings in Solventum were worth $1,980,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Newport Trust Company LLC purchased a new stake in shares of Solventum during the 2nd quarter valued at about $98,976,000. Baupost Group LLC MA bought a new stake in Solventum during the second quarter worth approximately $96,242,000. Hotchkis & Wiley Capital Management LLC purchased a new stake in Solventum during the third quarter valued at approximately $125,488,000. Trian Fund Management L.P. raised its position in Solventum by 32.9% during the third quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock valued at $496,842,000 after purchasing an additional 1,765,676 shares during the period. Finally, Magnetar Financial LLC lifted its stake in shares of Solventum by 2,880.8% in the 2nd quarter. Magnetar Financial LLC now owns 1,490,410 shares of the company’s stock valued at $78,813,000 after purchasing an additional 1,440,410 shares during the last quarter.

Solventum Stock Performance

SOLV stock opened at $72.72 on Friday. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $96.05. The firm’s 50-day moving average is $69.14 and its 200 day moving average is $65.29. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45.

Analyst Upgrades and Downgrades

SOLV has been the topic of several recent research reports. Stifel Nicolaus initiated coverage on Solventum in a report on Tuesday, October 8th. They set a “buy” rating and a $82.00 price target on the stock. Wolfe Research began coverage on shares of Solventum in a research report on Thursday, September 26th. They set a “peer perform” rating on the stock. Morgan Stanley raised their target price on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Piper Sandler upped their price target on shares of Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a report on Friday, November 8th. Finally, Mizuho started coverage on shares of Solventum in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price objective for the company. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, Solventum has an average rating of “Hold” and an average target price of $68.29.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.